US 12,329,787 B2
Microbial compositions for the treatment of skin diseases
Jared Kehe, Cambridge, MA (US); Bernardo Cervantes, Cambridge, MA (US); Cheri Ackerman, Somerville, MA (US); Abdulrahman Hassaballah, Boston, MA (US); and Keaton Armentrout, Seattle, WA (US)
Assigned to Concerto Biosciences, Inc., Cambridge, MA (US)
Filed by Concerto Biosciences, Inc., Cambridge, MA (US)
Filed on Sep. 5, 2024, as Appl. No. 18/825,396.
Application 18/825,396 is a continuation of application No. 18/589,539, filed on Feb. 28, 2024, granted, now 12,115,197.
Application 18/589,539 is a continuation of application No. PCT/US2022/079637, filed on Nov. 10, 2022.
Claims priority of provisional application 63/278,134, filed on Nov. 11, 2021.
Prior Publication US 2024/0424033 A1, Dec. 26, 2024
Int. Cl. A61K 35/74 (2015.01); A61K 31/51 (2006.01); A61K 35/741 (2015.01); A61P 31/04 (2006.01); C12N 1/20 (2006.01); C12R 1/07 (2006.01)
CPC A61K 35/741 (2013.01) [A61K 31/51 (2013.01); A61P 31/04 (2018.01); C12N 1/20 (2013.01); C12R 2001/07 (2021.05)] 27 Claims
 
1. A topical composition, wherein the topical composition is formulated for delivery to a skin in a form selected from an emulsion, a cream, a lotion, a gel, a foam, a powder, an ointment, or an oil, and comprises: cell free components of a cultured bacterial strain, wherein the cultured bacterial strain comprises a 16S rRNA gene sequence with at least 98% sequence identity to SEQ ID NO: 5 and a nucleic acid with a sequence with at least 98% sequence identity to SEQ ID NO: 13, and wherein the cell free components are present in an amount sufficient for suppression of Staphylococcus aureus growth on the skin.